Experience

Aliri

• France
• Biotechnology
• 1 - 100 Employee

• Chief Executive Officer

  • Jul 2021 - 2 years 6 months

  Aliri is committed to solving industry challenges by bringing innovative bioanalysis and spatial solutions to biotech and pharma, as the complexity of the drug development landscape continues to rise. With 3 facilities in USA and France, our mission is to support our customers with bringing life-saving therapies to market with speed and agility. We are focused on providing pharma and biotech companies with bioanalysis lab, spatial bioanalysis, and spatial biology solutions that will bring… Show more Aliri is committed to solving industry challenges by bringing innovative bioanalysis and spatial solutions to biotech and pharma, as the complexity of the drug development landscape continues to rise. With 3 facilities in USA and France, our mission is to support our customers with bringing life-saving therapies to market with speed and agility. We are focused on providing pharma and biotech companies with bioanalysis lab, spatial bioanalysis, and spatial biology solutions that will bring unique, comprehensive data to enable strategic decision making for lead optimization and strengthen regulatory submissions. Show less



Vaxinano

• France
• Biotechnology Research
• 1 - 100 Employee

• Angel Investor

  • Oct 2023 - 3 months

  France Biotechnology company specializing in the development of prophylactic and therapeutic vaccines to fight against infectious diseases in human and animal health. We offer a vaccine platform from which innovative, adjuvant-free vaccines are developed. This platform makes it possible to develop new vaccines, improve existing vaccines (replacement of adjuvants) and reduce/replace the use of antibiotics.



Charlie

• France
• IT Services and IT Consulting
• 1 - 100 Employee

• Angel Investor

  • Jun 2023 - 7 months



APTEEUS

• France
• Biotechnology Research
• 1 - 100 Employee

• Board Adviser

  • Jan 2023 - 1 year

  Apteeus has developed unique know-how and technology dedicated to drug discovery and repositioning. We are interested in pathologies for which the medical need is important and largely unsatisfied, particularly rare monogenic diseases. Our technology allows us to carry out discovery projects in a few months, and to identify new drug candidates. We work in collaboration with patient associations, doctors and academic and industrial partners. Our activity breaks with the classic drug discovery… Show more Apteeus has developed unique know-how and technology dedicated to drug discovery and repositioning. We are interested in pathologies for which the medical need is important and largely unsatisfied, particularly rare monogenic diseases. Our technology allows us to carry out discovery projects in a few months, and to identify new drug candidates. We work in collaboration with patient associations, doctors and academic and industrial partners. Our activity breaks with the classic drug discovery scheme and aims for a rapid and significant social impact. Show less



Hemerion Therapeutics

• France
• Biotechnology Research
• 1 - 100 Employee

• Angel Investor

  • Apr 2022 - 1 year 9 months

  France A disruptive technology to tackle brain cancer and glioblastoma



Aliri

• France
• Biotechnology
• 1 - 100 Employee

• CEO ImaBiotech Group

  • 2018 - May 2023

  Boston Located in Billerica (MA, USA) and North of Paris (France), ImaBiotech is a Contract Research Organisation (CRO) which offers innovative imaging services to support drug efficacy and toxicity from preclinical to clinical stages. ImaBiotech's team of experts develops and uses molecular Quantitative Mass Spectrometry Imaging technologies (label free technique) to support pathologists and pharmacologists to identify where the drugs are located in tissue and cells and how they impact cells… Show more Located in Billerica (MA, USA) and North of Paris (France), ImaBiotech is a Contract Research Organisation (CRO) which offers innovative imaging services to support drug efficacy and toxicity from preclinical to clinical stages. ImaBiotech's team of experts develops and uses molecular Quantitative Mass Spectrometry Imaging technologies (label free technique) to support pathologists and pharmacologists to identify where the drugs are located in tissue and cells and how they impact cells responses. The company has been founded by the expert team of MALDI molecular imaging. All these criteria have been combined with an innovative technological platform for an ultimate aim: Accelerate the discovery and the development of new molecules in the fields of Medicine, Pharmaceutics and Cosmetics industries.

• CEO France

  • Jun 2009 - Aug 2018

  Région de Lille, France



University of Lille 1 Sciences and Technology

• France
• Higher Education
• 700 & Above Employee

• External Lecturer

  • 2014 - 2018

  Lille Area, France External Lecturer - Introduction to General Strategy (Defining Strategy, Business Strategy and Marketing Strategy) to Master Degree Students.



LMR Lille métropole rugby

• President

  • Dec 2015 - Sep 2016

  Lille Area, France



AMOLF

• Netherlands
• Research Services
• 100 - 200 Employee

• Post-Doc - Analytical chemist

  • 2007 - Jun 2009

  MEDITRANS European project : Development of Molecular mass spectrometry Imaging to define drug distribution and its effects in pathologies.



CNRS

• France
• Research Services
• 700 & Above Employee

• Scientist

  • Sep 2004 - Sep 2007

  Région de Lille, France Ph-D with industrial partnership, under the direction of Salzet Michel and Isabelle Fournier (MALDI Imaging Team, Univ of Sciences and Technologies of Lille– France) Aim: - Development of MALDI Imaging in both FFPE and Frozen tissues. - Development of specific Imaging Mass spectrometry (US Patent) - Identification and characterization of biomarkers in ovary cancer tissues and Parkinson Disease. - Management of Master students and Teaching. Publications: - Molecular… Show more Ph-D with industrial partnership, under the direction of Salzet Michel and Isabelle Fournier (MALDI Imaging Team, Univ of Sciences and Technologies of Lille– France) Aim: - Development of MALDI Imaging in both FFPE and Frozen tissues. - Development of specific Imaging Mass spectrometry (US Patent) - Identification and characterization of biomarkers in ovary cancer tissues and Parkinson Disease. - Management of Master students and Teaching. Publications: - Molecular and Cellular Proteomics, 2006. - Journal Of Proteome research, 2006. - Medecine Science, 2006. - Current Pharmaceuticals design, 2007. - Journal of Proteome Research, 2007.

• Engineer

  • Mar 2004 - Sep 2004

  Within the LSMBO team - Pr Alain VAN DORSSELAER - Research biomarkers in the Alzheimer disease by a new purification approach: ClinProt (magnetic beads) - Installation and optimization of the ClinProt platform (Bruker). - Search for SNPs by using genopure (Bruker)